KR880012631A - 데스아자푸린- 누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도 - Google Patents

데스아자푸린- 누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도 Download PDF

Info

Publication number
KR880012631A
KR880012631A KR1019880004081A KR880004081A KR880012631A KR 880012631 A KR880012631 A KR 880012631A KR 1019880004081 A KR1019880004081 A KR 1019880004081A KR 880004081 A KR880004081 A KR 880004081A KR 880012631 A KR880012631 A KR 880012631A
Authority
KR
South Korea
Prior art keywords
group
compound
formula
denotes
hydroxyl
Prior art date
Application number
KR1019880004081A
Other languages
English (en)
Inventor
젤라 프랑크
무트 하인쯔-페터
카이저 클라우스
보우르 게오이스 베르너
뮐레거 클라우스
폰 데어 엘쯔 레르베르트
바쓰 한스-게오로크
Original Assignee
다움, 포우퀘트
뵈링거 만하임 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다움, 포우퀘트, 뵈링거 만하임 게엠베하 filed Critical 다움, 포우퀘트
Publication of KR880012631A publication Critical patent/KR880012631A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

데스아자푸린-누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 다음 일반식(I)의 데스아자푸린-누클레오시드 유도체, 이들의 토오토머, 이들의 염, 그리고 하나 또는 그 이상의 이들 일반식(I) 화합물을 구조적 성분으로 함유하는 헥산:
    상기식에서 X는 질소원자 또는 메틴기이고, W은 질소원자 또는 C-R4기이고, 같거나 또는 서로 다른 R1,R2,R3및 R4는 수소원자, 할로겐원자, 히드록실그룹, 메르캡토그룹, 저급알킬기, 저급알킬티오기, 저급알콕시, 아르알킬기, 아르알콕시기, 아릴옥시기 또는 한번 또는 두번 임의로 치환된 아미노그룹이고, R5는 수소원자 또는 히드록실 그룹이고, R6및 R7는 각각 수소원자 이거나 또는 이들중의 하나는 할로겐원자, 시아노그룹, 아지도르룹, 또는 한번 또는 두번 임의로 치환된 아미노그룹이고, 또한 X가 메틴기일 때에는 R6와 R7중의 하나는 히도록실그룹일 수 있고, 그 밖에 R5와 R7은 함께 C-2'와 C-3'사이의 원자가 결합을 더욱더 나타낼 수 있고, Y는 수소원자 또는 모노-, 디-또는 트리포스페이트그룹이다.
  2. 앞에서 상세하게 예시되어 있는 제1항에 따른 데스아자푸린-누클레오시드 유도체.
  3. 다음 일반식(II)의 화합물을 다음 일반식(III)의 화합물과 반응시켜 다음 일반식(IV)의 화합물을 얻고 , 이 화합물에 임의로 존재하는 산소 보호그룹을 떼어내고 5'-히드록실그룹을 선택적으로 보호한 후 R6또는 R7이 히드록실 그룹인 화합물을 얻고, 이 화합물을 할라이드, 시아나이드 또는 아자이드를 사용하여 R6또는 R7이 할로겐원자, 시아노그룹 또는 아지도그룹인 일반식(I)의 화합물로 공지된 방식으로 전환하거나 또는 공지된 방식으로 탈산소 반응시켜 R6또는 R7이 수소원자인 일반식(I)의 화합물을 얻고, 또는 이렇게 얻어진 일반식(I)의 화합물 중에 R6또는 R7이 아지도그룹인 화합물을 공지된 방식으로 전환시켜 R6또는 R7이 아미노그룹인 일반식(I)의 화합물을 얻고, 그리고 필요하다면, 이렇게 얻어진 일반식(I)의 화합물을 모노-, 디-또는 트리-포스페이트로 공지된 방식에 따라 전환하고, 또 필요하다면, 얻어진 유리염기 또는 산을 적절한 염으로 전환하거나 또는 얻어진 염을 해당하는 유리염기 또는 산으로 전환함을 특징으로 하는 일반식(I)화합물의 제조방법.
    상기식에서 X,W,R1,R2,R3, 및 R5는 상기에 정의된 바와같고, R6'및 R7'각각 수소원자이거나 또는 이들중의 하나는 산소 보호그룹에 의해 보호된 히드록실 그룹 또는 아지도 그룹이고, R'은 산소보호그룹이고, Z는 반응성 그룹이다.
  4. 실제적으로 앞에서 기재되고 예시된 바와 같은 제1항에 따른 화합물의 제조방법.
  5. 제3 또는 4항에 따른 방법에 의해 제조된 제1항에 따른 화합물
  6. DNA배열을 위한 제1항에 따른 화합물의 용도.
  7. 안티바이러스제로서 제1항에 따른 화합물의 용도.
  8. 제1항에 따른 최소한 하나의 화합물, 적절한 담체 및 조절제를 함유하는 약제학적 조성물.
  9. 약제학적 조성물의 제조를 위한 제1항에 따른 화합물들의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880004081A 1987-04-10 1988-04-09 데스아자푸린- 누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도 KR880012631A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3712280 1987-04-10
DEP3712280.0 1987-04-14
DE19873739366 DE3739366A1 (de) 1987-04-10 1987-11-20 Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
DEP3739366.9 1987-11-20

Publications (1)

Publication Number Publication Date
KR880012631A true KR880012631A (ko) 1988-11-28

Family

ID=25854556

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004081A KR880012631A (ko) 1987-04-10 1988-04-09 데스아자푸린- 누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도

Country Status (11)

Country Link
EP (1) EP0286028B1 (ko)
JP (2) JPH0662663B2 (ko)
KR (1) KR880012631A (ko)
CN (1) CN88102038A (ko)
AT (1) ATE124415T1 (ko)
AU (1) AU597483B2 (ko)
CA (1) CA1311201C (ko)
DE (2) DE3739366A1 (ko)
DK (1) DK194688A (ko)
ES (1) ES2076146T3 (ko)
HU (1) HU199871B (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293727C (en) * 1986-08-26 1991-12-31 Catherine Rose Kostlan 9-deazaguanines
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
WO1990006312A1 (de) * 1988-11-29 1990-06-14 Institut Für Molekularbiologie Und Analytik (Ima) Gmbh 2', 3'-didesoxyribofuranoside und ein verfahren zu ihrer herstellung
GB8902041D0 (en) * 1989-01-31 1989-03-22 Tanabe Seiyaku Co Antiviral agent and novel nucleoside
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
AU641183B2 (en) * 1989-09-19 1993-09-16 Teijin Limited Pyrrolo(2,3-d)pyrimidine derivative, process for preparing the same, and pharmaceutical preparation comprising the derivative as active ingredient
US5661148A (en) * 1989-09-19 1997-08-26 Teijin Limited Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient
JPH0637391B2 (ja) * 1989-09-29 1994-05-18 日本製紙株式会社 抗エイズウイルス剤
EP0604409B1 (en) * 1990-01-11 2004-07-14 Isis Pharmaceuticals, Inc. Oligonucleotide analogs for detecting and modulating rna activity and gene expression
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
DE4140463A1 (de) * 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
HU9501963D0 (en) * 1993-03-30 1995-08-28 Sterling Winthrop Inc 7-deazapurine modified oligonucleotides
AU6632094A (en) * 1993-04-19 1994-11-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
SE9500342D0 (sv) * 1995-01-31 1995-01-31 Marek Kwiatkowski Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation
US6054442A (en) * 1995-07-06 2000-04-25 Board Of Regents, University Of Texas System Methods and compositions for modulation and inhibition of telomerase in vitro
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US6291164B1 (en) 1996-11-22 2001-09-18 Invitrogen Corporation Methods for preventing inhibition of nucleic acid synthesis by pyrophosphate
EP0866070A1 (en) * 1997-03-20 1998-09-23 Amersham Pharmacia Biotech Inc Derivatives of 7 deaza 2' deoxy guanosine 5' triphosphate, preparation and use thereof
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
US6143206A (en) * 1998-06-24 2000-11-07 Tdk Corporation Organic positive temperature coefficient thermistor and manufacturing method therefor
US6452476B1 (en) 1999-01-28 2002-09-17 Tdk Corporation Organic positive temperature coefficient thermistor
US6093807A (en) * 1999-03-19 2000-07-25 Isis Pharmaceuticals, Inc. Sugar-modified 7-deaza-7-substituted oligonucleotides
US7169553B1 (en) 1999-08-30 2007-01-30 Roche Diagnostics, Gmbh 2-Azapurine compounds and their use
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
EP1236804A1 (en) 2001-03-02 2002-09-04 Boehringer Mannheim Gmbh A method for determination of a nucleic acid using a control
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
AU2003254657A1 (en) * 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
ES2617582T3 (es) * 2005-09-26 2017-06-19 Gilead Pharmasset Llc 4'-Nucleósidos modificados como agentes antivirales
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
CN101220071B (zh) * 2008-01-17 2011-04-06 南京长澳医药科技有限公司 稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EA201100446A1 (ru) 2008-09-08 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолопиримидины и их применение для лечения нарушений цнс
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
WO2011050938A1 (de) 2009-10-26 2011-05-05 Genovoxx Gmbh Konjugate von nukleotiden und methoden zu deren anwendung
CN103052639B (zh) 2010-08-12 2016-02-17 贝林格尔.英格海姆国际有限公司 6-环烷基-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮衍生物及其作为PDE9A抑制剂的用途
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
DE102012008375A1 (de) 2011-04-27 2012-10-31 Genovoxx Gmbh Methoden und Komponenten zur Detektion von Nukleinsäureketten
US20150086981A1 (en) 2011-05-04 2015-03-26 Genovoxx Gmbh Nucleoside-triphosphate conjugate and methods for the use thereof
GB201718804D0 (en) * 2017-11-14 2017-12-27 Nuclera Nucleics Ltd Novel use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315000A (en) * 1980-07-07 1982-02-09 Warner-Lambert Company β-D-Arabinofuranosylimidazo(4,5-c)pyridine compounds and methods for their production
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
DE3529478A1 (de) * 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
DD251984A5 (de) * 1985-09-17 1987-12-02 The Wellcome Foundation Limited,Gb Verfahren zur herstellung von 3'-azidonucleosiden und pharmazeutisch vertraeglichen derivaten davon
IN164556B (ko) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US5047519A (en) * 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
JPS63130599A (ja) * 1986-11-20 1988-06-02 Sekisui Chem Co Ltd 修飾ヌクレオチド

Also Published As

Publication number Publication date
HUT46703A (en) 1988-11-28
CA1311201C (en) 1992-12-08
HU199871B (en) 1990-03-28
DE3739366A1 (de) 1988-10-27
ES2076146T3 (es) 1995-11-01
JP2675749B2 (ja) 1997-11-12
EP0286028A3 (en) 1990-05-30
DK194688A (da) 1988-10-11
DK194688D0 (da) 1988-04-08
JPH0748396A (ja) 1995-02-21
CN88102038A (zh) 1988-10-26
JPS63275598A (ja) 1988-11-14
EP0286028A2 (de) 1988-10-12
EP0286028B1 (de) 1995-06-28
DE3854060D1 (de) 1995-08-03
AU1439888A (en) 1988-10-13
JPH0662663B2 (ja) 1994-08-17
ATE124415T1 (de) 1995-07-15
AU597483B2 (en) 1990-05-31

Similar Documents

Publication Publication Date Title
KR880012631A (ko) 데스아자푸린- 누클레오시드 유도체, 이들의 제조방법, 이들을 함유하는 제학적 조성물, 헥산 배열을 위한 이들의 용도 그리고 안티바이러스제로서 이들의 용도
KR880012605A (ko) 피라졸로[3,4-d]피리미딘, 이들의 제조방법 및 이들을 함유하는 제약조성물
KR890006650A (ko) 테트라하이드로-푸로 및 -티에노［2,3-c］피리딘, 약제학적 제제로서의 이의 용도 및 이의 제조방법
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
KR840008333A (ko) 피리미딘 유도체의 제조방법
KR830009046A (ko) 아로일 이미다졸론의 제조방법
ES8500900A1 (es) Procedimiento para preparar derivados de prolina disustituidos.
DK153545C (da) Analogifremgangsmaade til fremstilling af n-substituerede derivater af 3,4,5-trihydroxy-2-hydroxymethyl-piperidin
NO881701L (no) Middel for koservering av tre og trematerialer.
KR870008911A (ko) 카르보사이클릭 퓨린 누클레오시드, 그의 제조방법 및 용도
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
OA08835A (fr) Nouveaux dérivés de la 1,2,5,6-tétrahydropyridine, leur procédé de préparation, leur application comme médicaments et les compositions les renfermant.
ATE18226T1 (de) Pyrrolo(2,3-d)carbazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
KR840003631A (ko) 아졸릴펜옥시- 테트라하이드로푸란-2-일리덴- 메탄의 제조방법
CA2217026A1 (en) New antiviral substituted pyrimidinedione homocarbocyclic nucleoside derivatives and methods for the preparation thereof and compositions containing the same as active ingredients
KR910002891A (ko) 신규한 s-아데노실 메티오닌 디카르복실라제 억제제
EP0211489A3 (en) Derivatives of 2-fluoroalkylbenzimidazole, process for their preparation and pharmaceutical compositions containing them
KR910015537A (ko) 신규 1-아릴술포닐-2-피페리디논 유도체, 이의 제조방법, 제조용 중간체, 의약품으로서의 용도 및 이 화합물을 함유하는 조성물
KR840006480A (ko) 유기화합물 및 이의 제조방법
KR880003945A (ko) 신규화합물 및 그것의 제법, 그리고 그것의 약학적 조성물
KR900003195A (ko) 2'-메틸리덴피리미딘 뉴클레오시드 화합물, 그의 용도 및 제조방법
US4540798A (en) Antiatherosclerotic aminoethenyl furochromones
KR900016119A (ko) 치환 에텐류의 제조 방법
GB2005267A (en) Indole derivatives their preparation and pharmaceutical compositions containing them
DK0434560T3 (da) Hidtil ukendte substituerede aminosyrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid